234 related articles for article (PubMed ID: 27343324)
21. Diagnostic roles of neutrophil-to-lymphocyte ratio, monocyte-to-lymphocyte ratio, platelet-to-lymphocyte ratio, C-reactive protein, and cancer antigen 125 for ovarian cancer.
Ye L; Zhou G; Zhou L; Wang D; Xiong S; Liu C; Zhang G
J Int Med Res; 2023 Dec; 51(12):3000605231218557. PubMed ID: 38130127
[TBL] [Abstract][Full Text] [Related]
22. Roles of neutrophil/lymphocyte and platelet/lymphocyte ratios in the early diagnosis of malignant ovarian masses.
Yildirim MA; Seckin KD; Togrul C; Baser E; Karsli MF; Gungor T; Gulerman HC
Asian Pac J Cancer Prev; 2014; 15(16):6881-5. PubMed ID: 25169540
[TBL] [Abstract][Full Text] [Related]
23. Systemic Inflammatory Response Markers and CA-125 Levels in Ovarian Clear Cell Carcinoma: A Two Center Cohort Study.
Kim HS; Choi HY; Lee M; Suh DH; Kim K; No JH; Chung HH; Kim YB; Song YS
Cancer Res Treat; 2016 Jan; 48(1):250-8. PubMed ID: 25761476
[TBL] [Abstract][Full Text] [Related]
24. Combined neutrophil/platelet/lymphocyte/differentiation score predicts chemosensitivity in advanced gastric cancer.
Huang Z; Liu Y; Yang C; Li X; Pan C; Rao J; Li N; Liao W; Lin L
BMC Cancer; 2018 May; 18(1):515. PubMed ID: 29720123
[TBL] [Abstract][Full Text] [Related]
25. Postoperative human epididymis protein 4 predicts primary therapy outcome in advanced epithelial ovarian cancer.
Vallius T; Hynninen J; Auranen A; Matomäki J; Oksa S; Roering P; Grènman S
Tumour Biol; 2017 Feb; 39(2):1010428317691189. PubMed ID: 28218038
[TBL] [Abstract][Full Text] [Related]
26. Elevated plasma fibrinogen levels and prognosis of epithelial ovarian cancer: a cohort study and meta-analysis.
Luo Y; Kim HS; Kim M; Lee M; Song YS
J Gynecol Oncol; 2017 May; 28(3):e36. PubMed ID: 28382799
[TBL] [Abstract][Full Text] [Related]
27. Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial.
Katsumata N; Yasuda M; Isonishi S; Takahashi F; Michimae H; Kimura E; Aoki D; Jobo T; Kodama S; Terauchi F; Sugiyama T; Ochiai K;
Lancet Oncol; 2013 Sep; 14(10):1020-6. PubMed ID: 23948349
[TBL] [Abstract][Full Text] [Related]
28. The impact of pretreatment thrombocytosis and persistent thrombocytosis after adjuvant chemotherapy in patients with advanced epithelial ovarian cancer.
Lee M; Kim SW; Nam EJ; Yim GW; Kim S; Kim YT
Gynecol Oncol; 2011 Aug; 122(2):238-41. PubMed ID: 21531448
[TBL] [Abstract][Full Text] [Related]
29. Combined use of CA125, neutrophil/lymphocyte ratio and platelet/lymphocyte ratio for the diagnosis of borderline and malignant epithelial ovarian tumors.
Huang K; Xu S; Wang J; Ge L; Xu J; Jia X
J Ovarian Res; 2023 Feb; 16(1):37. PubMed ID: 36759870
[TBL] [Abstract][Full Text] [Related]
30. Prognostic Value of The Neutrophil-to-Lymphocyte Ratio, Platelet-to-Lymphocyte Ratio, and Platelet Count for Platinum-Sensitive Recurrent Epithelial Ovarian Cancer.
Sowannakul A; Rodpenpear N; Ekbhum P; Tantitamit T
Asian Pac J Cancer Prev; 2023 Nov; 24(11):3765-3771. PubMed ID: 38019234
[TBL] [Abstract][Full Text] [Related]
31. Dynamic Analysis of CA125 Decline During Neoadjuvant Chemotherapy in Patients with Epithelial Ovarian Cancer as a Predictor for Platinum Sensitivity.
Pelissier A; Bonneau C; Chéreau E; DE LA Motte Rouge T; Fourchotte V; Daraï E; Rouzier R
Anticancer Res; 2016 Apr; 36(4):1865-71. PubMed ID: 27069172
[TBL] [Abstract][Full Text] [Related]
32. A chemoresponse assay for prediction of platinum resistance in primary ovarian cancer.
Krivak TC; Lele S; Richard S; Secord AA; Leath CA; Brower SL; Tian C; Moore RG
Am J Obstet Gynecol; 2014 Jul; 211(1):68.e1-8. PubMed ID: 24530815
[TBL] [Abstract][Full Text] [Related]
33. Carboplatin plus paclitaxel as first-line chemotherapy in previously untreated advanced ovarian cancer. German AGO Study Group Ovarian Cancer. Arbeitsgemeinschaft Gynäkologische Onkologie.
du Bois A; Lück HJ; Meier W; Möbus V; Costa S; Richter B; Bauknecht T; Warm M; Schroeder W; Olbricht S; Nitz U; Jackisch C
Semin Oncol; 1997 Aug; 24(4 Suppl 11):S11-28-S11-33. PubMed ID: 9314296
[TBL] [Abstract][Full Text] [Related]
34. Dose-dense therapy is of benefit in primary treatment of ovarian cancer: contra.
van der Burg ME; Boere IA; Berns PM
Ann Oncol; 2011 Dec; 22 Suppl 8():viii33-viii39. PubMed ID: 22180397
[TBL] [Abstract][Full Text] [Related]
35. Are neutrophil/lymphocyte ratio and platelet/lymphocyte ratio associated with prognosis in patients with HER2-positive early breast cancer receiving adjuvant trastuzumab?
Ulas A; Avci N; Kos T; Cubukcu E; Olmez OF; Bulut N; Degirmenci M
J BUON; 2015; 20(3):714-22. PubMed ID: 26214622
[TBL] [Abstract][Full Text] [Related]
36. Diagnostic value of serum D-dimer, CA125, and neutrophil-to-lymphocyte ratio in differentiating ovarian cancer and endometriosis.
Chen L; Wang X; Shu J; Xu S; Wu Q; Yu Y
Int J Gynaecol Obstet; 2019 Nov; 147(2):212-218. PubMed ID: 31469423
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of whether serum tumor markers in patients with epithelial ovarian carcinoma change following chemotherapy.
Li XP; Xu QY; Wang JL; Wang SJ; Zhao Y; Wei LH
Chin Med J (Engl); 2012 Feb; 125(3):410-5. PubMed ID: 22490394
[TBL] [Abstract][Full Text] [Related]
38. A multicenter, non-randomized, phase II study of docetaxel and carboplatin administered every 3 weeks as second line chemotherapy in patients with first relapse of platinum sensitive epithelial ovarian, peritoneal or fallopian tube cancer.
Wang Y; Herrstedt J; Havsteen H; DePoint Christensen R; Mirza MR; Lund B; Maenpaa J; Kristensen G
BMC Cancer; 2014 Dec; 14():937. PubMed ID: 25494701
[TBL] [Abstract][Full Text] [Related]
39. Dose-dense therapy is of benefit in primary treatment of ovarian cancer? In favor.
Katsumata N
Ann Oncol; 2011 Dec; 22 Suppl 8():viii29-viii32. PubMed ID: 22180396
[TBL] [Abstract][Full Text] [Related]
40. Neutrophil-to-lymphocyte ratio is superior to platelet-to-lymphocyte ratio as a prognostic predictor in advanced non-small-cell lung cancer treated with first-line platinum-based chemotherapy.
Guo D; Li M; Chen D; Jing W; Zhu H; Fu L; Kong L; Yue J; Yu J
Future Oncol; 2019 Feb; 15(6):625-635. PubMed ID: 30430864
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
